Toll Free: 1-888-928-9744

Psoriasis - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 771 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Psoriasis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Psoriasis - Pipeline Review, H1 2016', provides an overview of the Psoriasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 Introduction 9 Psoriasis Overview 10 Therapeutics Development 11 Psoriasis - Therapeutics under Development by Companies 13 Psoriasis - Therapeutics under Investigation by Universities/Institutes 26 Psoriasis - Pipeline Products Glance 27 Psoriasis - Products under Development by Companies 31 Psoriasis - Products under Investigation by Universities/Institutes 49 Psoriasis - Companies Involved in Therapeutics Development 50 Psoriasis - Therapeutics Assessment 190 Drug Profiles 217 Psoriasis - Recent Pipeline Updates 562 Psoriasis - Dormant Projects 703 Psoriasis - Discontinued Products 729 Psoriasis - Product Development Milestones 734 Appendix 742
List of Tables
Number of Products under Development for Psoriasis, H1 2016 39 Number of Products under Development for Psoriasis - Comparative Analysis, H1 2016 40 Number of Products under Development by Companies, H1 2016 42 Number of Products under Development by Companies, H1 2016 (Contd..1) 43 Number of Products under Development by Companies, H1 2016 (Contd..2) 44 Number of Products under Development by Companies, H1 2016 (Contd..3) 45 Number of Products under Development by Companies, H1 2016 (Contd..4) 46 Number of Products under Development by Companies, H1 2016 (Contd..5) 47 Number of Products under Development by Companies, H1 2016 (Contd..6) 48 Number of Products under Development by Companies, H1 2016 (Contd..7) 49 Number of Products under Development by Companies, H1 2016 (Contd..8) 50 Number of Products under Development by Companies, H1 2016 (Contd..9) 51 Number of Products under Development by Companies, H1 2016 (Contd..10) 52 Number of Products under Development by Companies, H1 2016 (Contd..11) 53 Number of Products under Investigation by Universities/Institutes, H1 2016 54 Comparative Analysis by Late Stage Development, H1 2016 55 Comparative Analysis by Clinical Stage Development, H1 2016 56 Comparative Analysis by Early Stage Development, H1 2016 57 Comparative Analysis by Unknown Stage Development, H1 2016 58 Products under Development by Companies, H1 2016 59 Products under Development by Companies, H1 2016 (Contd..1) 60 Products under Development by Companies, H1 2016 (Contd..2) 61 Products under Development by Companies, H1 2016 (Contd..3) 62 Products under Development by Companies, H1 2016 (Contd..4) 63 Products under Development by Companies, H1 2016 (Contd..5) 64 Products under Development by Companies, H1 2016 (Contd..6) 65 Products under Development by Companies, H1 2016 (Contd..7) 66 Products under Development by Companies, H1 2016 (Contd..8) 67 Products under Development by Companies, H1 2016 (Contd..9) 68 Products under Development by Companies, H1 2016 (Contd..10) 69 Products under Development by Companies, H1 2016 (Contd..11) 70 Products under Development by Companies, H1 2016 (Contd..12) 71 Products under Development by Companies, H1 2016 (Contd..13) 72 Products under Development by Companies, H1 2016 (Contd..14) 73 Products under Development by Companies, H1 2016 (Contd..15) 74 Products under Development by Companies, H1 2016 (Contd..16) 75 Products under Development by Companies, H1 2016 (Contd..17) 76 Products under Investigation by Universities/Institutes, H1 2016 77 Psoriasis - Pipeline by 3SBio Inc., H1 2016 78 Psoriasis - Pipeline by 4SC AG, H1 2016 79 Psoriasis - Pipeline by Abeome Corporation, H1 2016 80 Psoriasis - Pipeline by AbGenomics International, Inc., H1 2016 81 Psoriasis - Pipeline by ADC Therapeutics Sarl, H1 2016 82 Psoriasis - Pipeline by Addex Therapeutics Ltd, H1 2016 83 Psoriasis - Pipeline by Advinus Therapeutics Ltd., H1 2016 84 Psoriasis - Pipeline by Affibody AB, H1 2016 85 Psoriasis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2016 86 Psoriasis - Pipeline by AlbireoPharma, H1 2016 87 Psoriasis - Pipeline by Almirall, S.A., H1 2016 88 Psoriasis - Pipeline by Amgen Inc., H1 2016 89 Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 90 Psoriasis - Pipeline by AnaptysBio, Inc., H1 2016 91 Psoriasis - Pipeline by ApoPharma Inc., H1 2016 92 Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 93 Psoriasis - Pipeline by Argos Therapeutics, Inc., H1 2016 94 Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 95 Psoriasis - Pipeline by AstraZeneca Plc, H1 2016 96 Psoriasis - Pipeline by Athenex, Inc., H1 2016 97 Psoriasis - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 98 Psoriasis - Pipeline by Avexxin AS, H1 2016 99 Psoriasis - Pipeline by BIOCAD, H1 2016 100 Psoriasis - Pipeline by Biocon Limited, H1 2016 101 Psoriasis - Pipeline by BioLingus AG, H1 2016 102 Psoriasis - Pipeline by BioMAS Ltd., H1 2016 103 Psoriasis - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 104 Psoriasis - Pipeline by Bionomics Limited, H1 2016 105 Psoriasis - Pipeline by Bionovis SA, H1 2016 106 Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 107 Psoriasis - Pipeline by Brickell Biotech, Inc., H1 2016 108 Psoriasis - Pipeline by Bristol-Myers Squibb Company, H1 2016 109 Psoriasis - Pipeline by C4X Discovery Holdings PLC, H1 2016 110 Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 111 Psoriasis - Pipeline by Celgene Corporation, H1 2016 112 Psoriasis - Pipeline by Cellceutix Corporation, H1 2016 113 Psoriasis - Pipeline by Celltrion, Inc., H1 2016 114 Psoriasis - Pipeline by ChemoCentryx, Inc., H1 2016 115 Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H1 2016 116 Psoriasis - Pipeline by ChironWells GmbH, H1 2016 117 Psoriasis - Pipeline by Coherus BioSciences, Inc., H1 2016 118 Psoriasis - Pipeline by Compugen Ltd., H1 2016 119 Psoriasis - Pipeline by Convoy Therapeutics, Inc., H1 2016 120 Psoriasis - Pipeline by Creabilis SA, H1 2016 121 Psoriasis - Pipeline by Crescendo Biologics Limited, H1 2016 122 Psoriasis - Pipeline by Curapel Limited, H1 2016 123 Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2016 124 Psoriasis - Pipeline by Domainex Limited, H1 2016 125 Psoriasis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 126 Psoriasis - Pipeline by Effimune SAS, H1 2016 127 Psoriasis - Pipeline by Eli Lilly and Company, H1 2016 128 Psoriasis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 129 Psoriasis - Pipeline by Exicure, Inc., H1 2016 130 Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 131 Psoriasis - Pipeline by Forward Pharma A/S, H1 2016 132 Psoriasis - Pipeline by Galectin Therapeutics, Inc., H1 2016 133 Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H1 2016 134 Psoriasis - Pipeline by Gene Signal International SA, H1 2016 135 Psoriasis - Pipeline by Genentech, Inc., H1 2016 136 Psoriasis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 137 Psoriasis - Pipeline by GlaxoSmithKline Plc, H1 2016 138 Psoriasis - Pipeline by GliaCure Inc., H1 2016 139 Psoriasis - Pipeline by GlycoMar Limited, H1 2016 140 Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 141 Psoriasis - Pipeline by Hydra Biosciences, Inc., H1 2016 142 Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 143 Psoriasis - Pipeline by Immune Pharmaceuticals Inc., H1 2016 144 Psoriasis - Pipeline by Immune Response BioPharma, Inc., H1 2016 145 Psoriasis - Pipeline by Immungenetics AG, H1 2016 146 Psoriasis - Pipeline by Innovent Biologics, Inc., H1 2016 147 Psoriasis - Pipeline by Invion Limited, H1 2016 148 Psoriasis - Pipeline by Jenrin Discovery, Inc., H1 2016 149 Psoriasis - Pipeline by Johnson & Johnson, H1 2016 150 Psoriasis - Pipeline by Kadmon Corporation, LLC, H1 2016 151 Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 152 Psoriasis - Pipeline by Kineta, Inc., H1 2016 153 Psoriasis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 154 Psoriasis - Pipeline by Lead Pharma Holding B.V., H1 2016 155 Psoriasis - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 156 Psoriasis - Pipeline by LEO Pharma A/S, H1 2016 157 Psoriasis - Pipeline by Lipidor AB, H1 2016 158 Psoriasis - Pipeline by Lupin Limited, H1 2016 159 Psoriasis - Pipeline by Mabion SA, H1 2016 160 Psoriasis - Pipeline by mAbxience S.A., H1 2016 161 Psoriasis - Pipeline by Maruho Co., Ltd., H1 2016 162 Psoriasis - Pipeline by MediGene AG, H1 2016 163 Psoriasis - Pipeline by Merck KGaA, H1 2016 164 Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 165 Psoriasis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 166 Psoriasis - Pipeline by Mycenax Biotech Inc., H1 2016 167 Psoriasis - Pipeline by Neovacs SA, H1 2016 168 Psoriasis - Pipeline by Nimbus Therapeutics, LLC, H1 2016 169 Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 170 Psoriasis - Pipeline by Novan, Inc., H1 2016 171 Psoriasis - Pipeline by Novartis AG, H1 2016 172 Psoriasis - Pipeline by Nuevolution AB, H1 2016 173 Psoriasis - Pipeline by Oncobiologics, Inc., H1 2016 174 Psoriasis - Pipeline by Panacea Biotec Limited, H1 2016 175 Psoriasis - Pipeline by Pfizer Inc., H1 2016 176 Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2016 177 Psoriasis - Pipeline by Pharmedartis GmbH, H1 2016 178 Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H1 2016 179 Psoriasis - Pipeline by PinCell srl, H1 2016 180 Psoriasis - Pipeline by Polichem S.A., H1 2016 181 Psoriasis - Pipeline by Promius Pharma, LLC, H1 2016 182 Psoriasis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 183 Psoriasis - Pipeline by Prothena Corporation Plc, H1 2016 184 Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 185 Psoriasis - Pipeline by RedHill Biopharma Ltd., H1 2016 186 Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 187 Psoriasis - Pipeline by Sandoz International GmbH, H1 2016 188 Psoriasis - Pipeline by Sareum Holdings Plc, H1 2016 189 Psoriasis - Pipeline by Selvita S.A., H1 2016 190 Psoriasis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2016 191 Psoriasis - Pipeline by Shulov Innovative Science Ltd., H1 2016 192 Psoriasis - Pipeline by Sigmoid Pharma Limited, H1 2016 193 Psoriasis - Pipeline by SignPath Pharma Inc, H1 2016 194 Psoriasis - Pipeline by Soligenix, Inc., H1 2016 195 Psoriasis - Pipeline by Spherium Biomed S.L., H1 2016 196 Psoriasis - Pipeline by Stemline Therapeutics, Inc., H1 2016 197 Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 198 Psoriasis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 199 Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 200 Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2016 201 Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2016 202 Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 203 Psoriasis - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016 204 Psoriasis - Pipeline by Telormedix SA, H1 2016 205 Psoriasis - Pipeline by TetraLogic Pharmaceuticals, H1 2016 206 Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 207 Psoriasis - Pipeline by Therapeutic Proteins International, LLC, H1 2016 208 Psoriasis - Pipeline by Therapix Biosciences Ltd, H1 2016 209 Psoriasis - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 210 Psoriasis - Pipeline by UCB S.A., H1 2016 211 Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 212 Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 213 Psoriasis - Pipeline by vTv Therapeutics LLC, H1 2016 214 Psoriasis - Pipeline by Wellstat Therapeutics Corporation, H1 2016 215 Psoriasis - Pipeline by Yuhan Corporation, H1 2016 216 Psoriasis - Pipeline by Ziarco Pharma Ltd, H1 2016 217 Assessment by Monotherapy Products, H1 2016 218 Assessment by Combination Products, H1 2016 219 Number of Products by Stage and Target, H1 2016 221 Number of Products by Stage and Mechanism of Action, H1 2016 233 Number of Products by Stage and Route of Administration, H1 2016 242 Number of Products by Stage and Molecule Type, H1 2016 244 Psoriasis Therapeutics - Recent Pipeline Updates, H1 2016 590 Psoriasis - Dormant Projects, H1 2016 731 Psoriasis - Dormant Projects (Contd..1), H1 2016 732 Psoriasis - Dormant Projects (Contd..2), H1 2016 733 Psoriasis - Dormant Projects (Contd..3), H1 2016 734 Psoriasis - Dormant Projects (Contd..4), H1 2016 735 Psoriasis - Dormant Projects (Contd..5), H1 2016 736 Psoriasis - Dormant Projects (Contd..6), H1 2016 737 Psoriasis - Dormant Projects (Contd..7), H1 2016 738 Psoriasis - Dormant Projects (Contd..8), H1 2016 739 Psoriasis - Dormant Projects (Contd..9), H1 2016 740 Psoriasis - Dormant Projects (Contd..10), H1 2016 741 Psoriasis - Dormant Projects (Contd..11), H1 2016 742 Psoriasis - Dormant Projects (Contd..12), H1 2016 743 Psoriasis - Dormant Projects (Contd..13), H1 2016 744 Psoriasis - Dormant Projects (Contd..14), H1 2016 745 Psoriasis - Dormant Projects (Contd..15), H1 2016 746 Psoriasis - Dormant Projects (Contd..16), H1 2016 747 Psoriasis - Dormant Projects (Contd..17), H1 2016 748 Psoriasis - Dormant Projects (Contd..18), H1 2016 749 Psoriasis - Dormant Projects (Contd..19), H1 2016 750 Psoriasis - Dormant Projects (Contd..20), H1 2016 751 Psoriasis - Dormant Projects (Contd..21), H1 2016 752 Psoriasis - Dormant Projects (Contd..22), H1 2016 753 Psoriasis - Dormant Projects (Contd..23), H1 2016 754 Psoriasis - Dormant Projects (Contd..24), H1 2016 755 Psoriasis - Dormant Projects (Contd..25), H1 2016 756 Psoriasis - Discontinued Products, H1 2016 757 Psoriasis - Discontinued Products (Contd..1), H1 2016 758 Psoriasis - Discontinued Products (Contd..2), H1 2016 759 Psoriasis - Discontinued Products (Contd..3), H1 2016 760 Psoriasis - Discontinued Products (Contd..4), H1 2016 761


List of Figures
Number of Products under Development for Psoriasis, H1 2016 39 Number of Products under Development for Psoriasis - Comparative Analysis, H1 2016 40 Number of Products under Development by Companies, H1 2016 41 Number of Products under Investigation by Universities/Institutes, H1 2016 54 Comparative Analysis by Late Stage Development, H1 2016 55 Comparative Analysis by Clinical Stage Development, H1 2016 56 Comparative Analysis by Early Stage Products, H1 2016 57 Assessment by Monotherapy Products, H1 2016 218 Assessment by Combination Products, H1 2016 219 Number of Products by Top 10 Targets, H1 2016 220 Number of Products by Stage and Top 10 Targets, H1 2016 220 Number of Products by Top 10 Mechanism of Actions, H1 2016 232 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 232 Number of Products by Top 10 Routes of Administration, H1 2016 241 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 241 Number of Products by Top 10 Molecule Types, H1 2016 243 Number of Products by Stage and Top 10 Molecule Types, H1 2016 243

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify